Anya Biopharm (ROCO:7776) Total Equity: NT$402.85 Mil (As of Dec. 2025)


ROCO:7776 Anya Biopharm Inc ROCO:7776
12 GF Score
Price NT$31.80
! 4 Warning Signs
View Full Analysis

What is Anya Biopharm Total Equity?

Anya Biopharm ROCO:7776 12 Total Equity is NT$402.85 Mil as of Dec. 2025. GuruFocus rates ROCO:7776 with a GF Score™ of 12/100. The stock has 4 warning signs investors should review.

Anya Biopharm's total equity for the quarter that ended in Dec. 2025 was NT$402.85 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Anya Biopharm Total Equity Historical Data

* Premium members only.

The historical data trend for Anya Biopharm's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anya Biopharm Total Equity Chart

Anya Biopharm Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Equity
-55.18 -83.26 466.97 402.85

Anya Biopharm Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial -83.26 473.64 466.97 398.50 402.85
ROCO:7776
12GF Score
Anya Biopharm Inc ROCO:7776
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anya Biopharm Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Anya Biopharm's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=413.871-11.022
=402.85

Anya Biopharm's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=413.871-11.022
=402.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$402.85 Mil mean?
Anya Biopharm (ROCO:7776) has a Total Equity of NT$402.85 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Anya Biopharm and its competitors.
Is Anya Biopharm's Total Equity too high?
Anya Biopharm's current Total Equity is NT$402.85 Mil. Overall, Anya Biopharm has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Anya Biopharm's Total Equity compare to VRTX and REGN?
Anya Biopharm's Total Equity of NT$402.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Anya Biopharm and its competitors. Anya Biopharm's current Total Equity is NT$402.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anya Biopharm stock overvalued right now?
Anya Biopharm (ROCO:7776) has a current Total Equity of NT$402.85 Mil. The current Total Equity is NT$402.85 Mil. Anya Biopharm's overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Anya Biopharm (ROCO:7776), the current Total Equity is NT$402.85 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anya Biopharm Business Description

Address No. 3-2, Yuanqu Street, 4th Floor, Nangang, Taipei, TWN, 115603
Anya Biopharm Inc is a pharmaceutical company engaged in the Oral Delivery of Peptides. Its patented technology platform Mira/Je is a flexible solution easy to adapt to a large variety of peptides.
12GF Score

Get the complete analysis for ROCO:7776

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.80
Price